
Understanding Keratoconus & the Importance of Early Diagnosis
Corneal Cross-Linking
Not long ago, a diagnosis of progressive keratoconus left patients with few treatment options.
Today, Avedro’s Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and KXL® system are FDA-approved for use in corneal cross-linking and provide patients with a one-time, minimally invasive therapeutic treatment to limit the progression of their condition
What is Keratoconus?
Keratoconus
[ker-uh-toh-koh-nuh s]
Keratoconus or “KC” is a non-inflammatory eye condition in which the normally round dome-shaped cornea progressively thins causing a cone-like bulge to develop. This results in significant visual impairment.


Who’s Affected by Keratoconus?

Keratoconus Affects Both Genders
although it is unclear whether significant differences exist between males and females2
The Disease is Also Found in Ethnic Groups
with some studies showing higher incidence rates among Asian populations, in particular

Keratoconus
is estimated to occur in
persons in the U.S. population
Signs & Symptoms of Keratoconus
usually first appear in the late teens and early twenties

Excessively Rubbing Eyes

Mildly Blurred Vision

Difficulty Seeing at Night

Frequent Changes in Eyeglass Prescription

Frequent Headaches

Vision that Cannot Be Corrected with Glasses
Risk Factors for Keratoconus
While the exact cause of keratoconus is unknown,
it is believed that genetics, the environment and the endocrine system all play a role
While the exact cause of keratoconus is unknown,
it is believed that genetics, the environment and the endocrine system all play a role
Some KC cases have a hereditary component and studies indicate that
OF PATIENTS HAVE AFFECTED RELATIVES

Importance of Early Detection
KC is a progressive condition which worsens over time, so early diagnosis is critical

Example of Keratoconus Progression Over Time*
*Individual outcomes may vary. The depiction may not reflect the typical keratoconus patient’s experience and the timeline may vary. It is not intended to represent or guarantee that anyone will have the same or similar outcomes.